Vaccines against coronavirus and methods of use
Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.
1. A nucleic acid molecule encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, the nucleic acid molecule comprising:
a nucleic acid sequence having at least 99% identity to the nucleic acid sequence set forth from nucleotide 55 to nucleotide 3837 of SEQ ID NO: 2;
the nucleic acid sequence from nucleotide 55 to nucleotide 3837 of SEQ ID NO: 2; or
the nucleic acid sequence of SEQ ID NO: 2.
2. An expression vector comprising a nucleic acid molecule encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, the nucleic acid molecule comprising:
a nucleic acid sequence having at least 99% identity to the nucleic acid sequence set forth from nucleotide 55 to nucleotide 3837 of SEQ ID NO: 2;
the nucleic acid sequence from nucleotide 55 to nucleotide 3837 of SEQ ID NO: 2; or
the nucleic acid sequence of SEQ ID NO: 2.
3. An immunogenic composition comprising an effective amount of an expression vector and a pharmaceutically acceptable excipient, wherein the expression vector comprises a nucleic acid molecule encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, the nucleic acid molecule comprising:
a nucleic acid sequence having at least 99% identity to the nucleic acid sequence set forth from nucleotide 55 to nucleotide 3837 of SEQ ID NO: 2;
the nucleic acid sequence from nucleotide 55 to nucleotide 3837 of SEQ ID NO: 2; or
the nucleic acid sequence of SEQ ID NO: 2.
4. The immunogenic composition according to claim 3 , wherein the pharmaceutically acceptable excipient comprises a buffer.
5. The immunogenic composition according to claim 4 , wherein the buffer is saline-sodium citrate buffer.
6. The immunogenic composition of claim 5 , wherein the composition comprises 10 mg of the vector per milliliter of saline-sodium citrate buffer.
7. The immunogenic composition according to claim 3 , further comprising an adjuvant.
8. A method of inducing an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof, the method comprising administering an effective amount of the immunogenic composition of claim 3 .
9. The method of claim 8 , wherein administering comprises at least one of electroporation and parenteral administration.
10. The method of claim 9 , wherein administering comprises parenteral administration followed by electroporation.
11. The method of claim 9 , wherein the parenteral administration is subcutaneous administration, intradermal administration, or intramuscular administration.
12. The method of claim 8 , wherein an initial dose of about 0.5 mg to about 2.0 mg of the vector is administered to the subject, optionally wherein the initial dose is 0.5 mg, 1.0 mg or 2.0 mg of the vector.
13. The method of claim 12 , wherein a subsequent dose of about 0.5 mg to about 2.0 mg of the vector is administered to the subject about four weeks after the initial dose, optionally wherein the subsequent dose is 0.5 mg, 1.0 mg or 2.0 mg of the vector.
14. The method of claim 13 , wherein one or more further subsequent doses of about 0.5 mg to about 2.0 mg of the vector is administered to the subject at least twelve weeks after the initial dose, optionally wherein the further subsequent dose is 0.5 mg, 1.0 mg, or 2.0 mg of the vector.
15. The method of claim 8 , wherein the immunogenic composition is INO-4800 or a biosimilar thereof.
16. The method of claim 8 , further comprising administering to the subject at least one additional agent for the treatment of SARS-CoV-2 infection or the treatment or prevention of a disease or disorder associated with SARS-CoV-2 infection.
17. The method of claim 16 , wherein the immunogenic composition is administered to the subject before, concurrently with, or after the additional agent.
18. The method of claim 8 , wherein the subject is thereby treated or protected against one or more SARS-CoV-2 strains.
19. The method of claim 8 , wherein the subject is thereby treated or protected against a disease or disorder associated with SARS-CoV-2 infection.
20. The method of claim 19 , wherein the disease or disorder associated with SARS-CoV-2 infection is Coronavirus Disease 2019 (COVID-19), Multisystem inflammatory syndrome in adults (MIS-A), or Multisystem inflammatory syndrome in children (MIS-C).
21. The expression vector of claim 2 , wherein the vector comprises the nucleic acid sequence of SEQ ID NO: 3.